Biotech1 year ago
Almirall and EpimAb Join Forces to Develop Biospecific Antibodies
Almirall will obtain a license to use EpimAb's patented Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform. The Spanish pharmaceutical company reduced its profit by 56% in the first half...